Emerging exploration has centered on a cohort of C5aR1-inhibiting antibodies: vonlerolizumab. These offer distinct methods to modulate C5aR1 pathway, aiming to alleviate inflammation in various inflammatory conditions. Despite each agent shares a mechanism of function, variations exist in the potency, targeting, and observed profile, requiring d… Read More

The appearance of troglitazone, a potent antidiabetic agent, marked a significant chapter in the treatment of type 2 diabetes. However, its withdrawal from the market due to severe hepatotoxicity spurred considerable investigation into related thiazolidinediones. Following pioglitazone and rosiglitazone emerged, offering akin mechanisms of actio… Read More